This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Luteal Phase Progesterone in IUI and Gonadotropin Cycles

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2013 by University of Alberta.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
University of Alberta Identifier:
First received: August 19, 2013
Last updated: December 31, 2014
Last verified: July 2013

This is a study of patients undergoing Controlled Ovarian Hyperstimulation (COH) with Gonadotropins and Intrauterine Insemination (IUI) at a Fertility Clinic.

Infertility is a common problem, and a popular method of therapy is to inject sperm through the cervix and into the uterus, a procedure known as IUI. In conjunction with IUI, injectable medications (gonadotropins) are used to stimulate the ovaries to produce more than one egg per cycle in a process called COH.

Vaginal progesterone is used for luteal support in in vitro fertilization therapy and has been proven to effect pregnancy rates. However, the role of progesterone in COH is still unclear. In this study, the investigators want to examine the effect of giving vaginal progesterone after COH with IUI on pregnancy rates. The investigators want to study if luteal vaginal progesterone results in a higher pregnancy rate compared to no progesterone therapy in COH with IUI. At present, fertility centres vary in the use of progesterone after insemination, most likely due to the lack of studies on this subject.

At the Fertility Clinic all patients undergoing COH with injectable medications and IUI, regardless of whether they are in the study, have a baseline transvaginal ultrasound and blood tests. Patients start the injectable medications for COH until the ovarian follicles are large enough, then a medication to release the eggs is given. The IUI is done approximately 36 hours later. The day after the IUI, study patients will be given vaginal progesterone while the control patients will receive no progesterone. All patients will be followed until a pregnancy test is done and a viable foetus is confirmed by ultrasound.

Condition Intervention Phase
Infertility Drug: Progesterone Effervescent Vaginal Tablets Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of Luteal Phase Support on Pregnancy Rate in Intrauterine Insemination Cycles Following Ovarian Stimulation With Gonadotropins

Resource links provided by NLM:

Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • Clinical pregnancy rate [ Time Frame: After 6 weeks gestational age ]
    Presence of a fetal heart beat after 6 weeks gestational age

Secondary Outcome Measures:
  • Biochemical Pregnancy [ Time Frame: After 6 weeks gestational age ]
    Biochemical pregnancy rate

  • Non-viable Pregnancy [ Time Frame: After 6 weeks gestational age ]
    Non-viable pregnancy rate

  • Multiple Pregnancy [ Time Frame: After 6 weeks gestational age ]
    Multiple pregnancy rate

Estimated Enrollment: 300
Study Start Date: July 2014
Estimated Study Completion Date: January 2016
Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: No Luteal Support
Control group: No luteal phase support or medication will be used
Experimental: Luteal Vaginal Progesterone
Experiment group: Vaginal progesterone for luteal support beginning the first day after IUI
Drug: Progesterone Effervescent Vaginal Tablets
Other Name: Endometrin 100 mg twice daily


Ages Eligible for Study:   21 Years to 43 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Couples with infertility
  • Confirmed bilateral tubal patency
  • More than 10 million motile sperm available for IUI

Exclusion Criteria:

  • Subjects declining enrollment
  • Allergies to prescribed vaginal progesterone
  • Subjects less than 21 years old or over 43 years old
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01941875

Contact: Tarek Motan, MB ChB 780-735-5604
Contact: Jinglan Han, MD 780-735-5604

Canada, Alberta
Fertility & Womens Endocrine Clinic, Royal Alexandra Hospital Recruiting
Edmonton, Alberta, Canada, T5H 3V9
Contact: Tarek Motan, MB ChB    780-735-5604   
Contact: Jinglan Han, MD    780-735-5604   
Principal Investigator: Tarek Motan, MB ChB         
Sub-Investigator: Jinglan Han, MD         
Sponsors and Collaborators
University of Alberta
  More Information

Responsible Party: University of Alberta Identifier: NCT01941875     History of Changes
Other Study ID Numbers: Pro00032793
Study First Received: August 19, 2013
Last Updated: December 31, 2014

Keywords provided by University of Alberta:
controlled ovarian hyperstimulation
intrauterine insemination
luteal progesterone

Additional relevant MeSH terms:
Genital Diseases, Male
Genital Diseases, Female
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on June 22, 2017